Home » Topics » Regulatory » EMA

EMA
RSS

E.U. orphan drug status recommended for ALN-TTR01 in familial amyloidotic polyneuropathy

Jan. 27, 2011

CHMP recommends approval of Pravafenix

Jan. 26, 2011

CHMP recommends new indications of INOmax

Jan. 25, 2011

CHMP recommends European marketing authorization for Trobalt

Jan. 25, 2011

CHMP issues positive opinion on Eisai's Halaven for metastatic breast cancer

Jan. 25, 2011

CHMP decides against approval of Fampyra to improve walking in MS

Jan. 24, 2011

CHMP recommends approval of Jevtana combination regimen for prostate cancer

Jan. 24, 2011

CHMP adopts final negative opinion for cladribine tablets in relapsing-remitting MS

Jan. 24, 2011

CHMP adopts positive opinion for Gilenya in relapsing-remitting MS

Jan. 24, 2011

CHMP issues positive opinion on European orphan drug status for darinaparsin in PTCL

Jan. 21, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...